KalVista - KalVista Pharmaceuticals
2024年10月2日 · At KalVista, we are working to empower people to enjoy everyday life beyond the challenges of their disease. With our scientific advances in orally-delivered small molecule medicines, we aim to change the treatment landscape to address the unmet needs of people living with hereditary angioedema (HAE).
KalVista Pharmaceuticals Logo - CompaniesLogo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
KalVista Pharmaceuticals, Inc. | LinkedIn
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our...
Fey’s logo database
Download a free SVG and JSX logo of KalVista Pharmaceuticals. Fey logos is extensive collection of thousands of detailed, scalable vector logos from top public companies, meticulously created by hand.
KalVista Pharmaceuticals, Inc. (KALV) - Yahoo Finance
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet...
News Releases - KalVista Pharmaceuticals
Oct 04, 2024. KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum. –New data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often– –Patient perspectives spotlight the prevalence of anxiety when faced ...
KalVista Pharmaceuticals, Inc. (KALV) - Stock Analysis
6 天之前 · KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
KalVista Company Profile 2024: Stock Performance & Earnings
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral ...
KalVista Pharmaceuticals Company Profile - Office Locations ...
2024年8月16日 · KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause …
- 某些结果已被删除